Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells - PubMed (original) (raw)
Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells
D Bhaumik et al. Oncogene. 2008.
Abstract
Cancer cells often acquire a constitutively active nuclear factor-kappaB (NF-kappaB) program to promote survival, proliferation and metastatic potential by mechanisms that remain largely unknown. Extending observations from an immunologic setting, we demonstrate that microRNA-146a and microRNA-146b (miR-146a/b) when expressed in the highly metastatic human breast cancer cell line MDA-MB-231 function to negatively regulate NF-kappaB activity. Lentiviral-mediated expression of miR-146a/b significantly downregulated interleukin (IL)-1 receptor-associated kinase and TNF receptor-associated factor 6, two key adaptor/scaffold proteins in the IL-1 and Toll-like receptor signaling pathway, known to positively regulate NF-kappaB activity. Impaired NF-kappaB activity was evident from reduced phosphorylation of the NF-kappaB inhibitor IkappaBalpha, reduced NF-kappaB DNA-binding activity and suppressed expression of the NF-kappaB target genes IL-8, IL-6 and matrix metalloproteinase-9. Functionally, miR-146a/b-expressing MDA-MB-231 cells showed markedly impaired invasion and migration capacity relative to control cells. These findings implicate miR-146a/b as a negative regulator of constitutive NF-kappaB activity in a breast cancer setting and suggest that modulating miR-146a/b levels has therapeutic potential to suppress breast cancer metastases.
Figures
Figure 1. IRAK1 and TRAF6 protein levels are reduced in MDA-MB-231 cells overexpressing miRNA-146a and miR-146b
(a) Northern blot of total RNA prepared from control MDA-MB-231 cells (C), miR-146a-expressing MDA-MB-231 cells (146a) and miR-146b-expressing MDA-MB-231 cells (146b) was probed with an antisense miR-146b DNA oligo (right panel), stripped and reprobed with an antisense miR-146a DNA oligo (left panel). Northern blot was performed as previously described (Scott et al., 2007). Mature and pre-miRNA species are noted. RNA loading was confirmed by probing for the small RNA species, U6 RNA (bottom panel). The lentiviral miR-146a/b expression vectors were constructed by cloning 146 bp of pri miR-146a sequence and 120 bp of pri miR-146b sequence that included the terminal loop, the upper stem and the lower stem with 10 bp of upstream/downstream flanking genomic sequence into a site under cytomegalovirus promoter control. (b) Western blot of total protein lysates prepared from MDA-MB-231 cell pools as described in Figure 1a was probed for IRAK1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The ratio of IRAK1 to β-actin band intensity for each lysate was normalized to the control ratio as shown below the western panel. (c) Northern blot using total RNA isolated from MDA-MB-231 cells as described in (a) was probed for IRAK1. Reprobing the blot for GAPDH established equal RNA loading. The IRAK1 3.2-kb transcript size was deduced from the ethidium-stained gel 18S (1.9 kb) and 28S (5.0 kb) bands. (d) Western blot of total protein lysates as described in (b) was probed for TRAF6 (sc-7221; Santa Cruz Biotechnology). GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IRAK1, IL-1 receptor-associated kinase; miRNA, microRNA; TRAF6, tumour-necrosis factor receptor-associated factor 6.
Figure 2. MDA-MB-231 cells overexpressing miR-146a/b have reduced phosphorylation of the NF-κB inhibitor IκBα and reduced NF-κB DNA-binding activity
(a) Western blot of total protein lysates prepared from MDA-MB-231 cell pools as described in Figure 1a was probed for phosphorylated IκBα protein (Ser 32; Cell Signaling Technology, Danvers, MA, USA), stripped and reprobed for total IκBα protein (top panel). The ratio of phosphorylated band intensity to total band intensity was normalized as in Figure 1b and shown below the western panel. Western blot in the lower panel shows that levels of NF-κB (65 kDa) are equal in control cells and miR-146a/b-expressing cells relative to β-actin. (b) EMSA for binding to a consensus NF-κB DNA oligo probe using control (C), miR-146a (146a) and miR-146b (146b) nuclear extracts loaded in duplicate lanes (left panel). The position of the gel origin, NF-κB gel shifted band and free probe are indicated. Right panel shows specificity of NF-κB DNA binding as antibodies to the p65 and p50 subunits of NF-κB supershifted the NF-κB band (p65 Ab and p50 Ab lanes) whereas a control antibody (con Ab, an estrogen receptor antibody) had no effect. Bottom panel: western blot of nuclear extracts used for EMSA probed for HDAC2 (Santa Cruz Biotechnology) shows equal protein content of the extracts. HDAC2, histone deacetylase 2; miR, microRNA; NF-κB, nuclear factor-κB; EMSA, electrophoretic gel shift assays.
Figure 3. IL-8 mRNA level together with IL-8, IL-6and MMP-9 protein levels are downregulated in cells overexpressing miR-146a/b
(a) Northern blot prepared as described in Figure 1a was probed for IL-8. RNA loading was established by probing the blot with GAPDH. (b) Western blot using TCA-precipitated proteins from conditioned media containing 0.2% serum collected over 24 h was probed for IL-8 (R&D Systems, Minneapolis MN, USA), IL-6 (R&D Systems), MMP-9 (NeoMarkers, Fremont, CA, USA) and IGFBP3 (Santa Cruz Biotechnology). GAPDH, glyceraldehyde-3-phosphate dehydrogenase; miR, microRNA; MMP-9, matrix metalloproteinase 9; TCA, trichloroacetic acid; IGFBP3, insulin like growth factor binding protein-3.
Figure 4. MDA-MB-231 cells overexpressing miR-146a/b have significantly reduced capacity to invade through Matrigel and migrate
(a) Typical field of a Matrigel invasion insert showing the reduced number of invading miR-146a- and miR-146b-expressing cells compared to control cells (8 µm BioCoat Growth Factor Reduced Matrigel Invasion Chambers; BD Biosciences, San Jose, CA, USA). Cells were plated in triplicate at 1 × 105 cells per insert in DMEM media with 10 ng/ml recombinant EGF in DMEM media used as the chemoattractant in the lower chambers for both invasion and migration assays. Following 20 h of incubation, inserts were processed according to the manufacturer’s recommendations using 1% Toluidine Blue. Stained membranes were photographed using an Olympus I × 70 microscope at × 70. b Quantification of invasion achieved by the miR-146a and miR-146b cells as a percentage of that achieved by control cells. Cell counts were determined from the average of five random fields (each field capturing approximately 6% of total membrane area). (c) Quantification of migration through 8-µm pore inserts (BD Biosciences) by miR-146a- and miR-146b-expressing cells as a percentage of that achieved by control cells. All cell-invasion and migration assays were repeated in three independent experiments using the lentiviral-infected miR-146a, miR-146b and control cell pools. DMEM, Dulbecco’s modified Eagle’s medium; miR, microRNA; EGF, epidermal growth factor.
Similar articles
- Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis.
Hurst DR, Edmonds MD, Scott GK, Benz CC, Vaidya KS, Welch DR. Hurst DR, et al. Cancer Res. 2009 Feb 15;69(4):1279-83. doi: 10.1158/0008-5472.CAN-08-3559. Epub 2009 Feb 3. Cancer Res. 2009. PMID: 19190326 Free PMC article. - MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-κB and TGF-β signaling pathways.
Keklikoglou I, Koerner C, Schmidt C, Zhang JD, Heckmann D, Shavinskaya A, Allgayer H, Gückel B, Fehm T, Schneeweiss A, Sahin O, Wiemann S, Tschulena U. Keklikoglou I, et al. Oncogene. 2012 Sep 13;31(37):4150-63. doi: 10.1038/onc.2011.571. Epub 2011 Dec 12. Oncogene. 2012. PMID: 22158050 - MicroRNA-146a negatively regulates inflammation via the IRAK1/TRAF6/NF-κB signaling pathway in dry eye.
Han R, Gao J, Wang L, Hao P, Chen X, Wang Y, Jiang Z, Jiang L, Wang T, Zhu L, Li X. Han R, et al. Sci Rep. 2023 Jul 11;13(1):11192. doi: 10.1038/s41598-023-38367-4. Sci Rep. 2023. PMID: 37433841 Free PMC article. - MicroRNA-146a and microRNA-146b regulate human dendritic cell apoptosis and cytokine production by targeting TRAF6 and IRAK1 proteins.
Park H, Huang X, Lu C, Cairo MS, Zhou X. Park H, et al. J Biol Chem. 2015 Jan 30;290(5):2831-41. doi: 10.1074/jbc.M114.591420. Epub 2014 Dec 11. J Biol Chem. 2015. PMID: 25505246 Free PMC article. - Sinomenine inhibits breast cancer cell invasion and migration by suppressing NF-κB activation mediated by IL-4/miR-324-5p/CUEDC2 axis.
Song L, Liu D, Zhao Y, He J, Kang H, Dai Z, Wang X, Zhang S, Zan Y. Song L, et al. Biochem Biophys Res Commun. 2015 Aug 28;464(3):705-10. doi: 10.1016/j.bbrc.2015.07.004. Epub 2015 Jul 10. Biochem Biophys Res Commun. 2015. PMID: 26166821
Cited by
- Specific Roles of MicroRNAs in Their Interactions with Environmental Factors.
Wang J, Cui Q. Wang J, et al. J Nucleic Acids. 2012;2012:978384. doi: 10.1155/2012/978384. Epub 2012 Oct 31. J Nucleic Acids. 2012. PMID: 23209884 Free PMC article. - microRNAs Shape Myeloid Cell-Mediated Resistance to Cancer Immunotherapy.
Daveri E, Vergani E, Shahaj E, Bergamaschi L, La Magra S, Dosi M, Castelli C, Rodolfo M, Rivoltini L, Vallacchi V, Huber V. Daveri E, et al. Front Immunol. 2020 Jul 22;11:1214. doi: 10.3389/fimmu.2020.01214. eCollection 2020. Front Immunol. 2020. PMID: 32793185 Free PMC article. Review. - Therapeutic Implication of miRNAs as an Active Regulatory Player in the Management of Pain: A Review.
Hassan M, Shahzadi S, Yasir M, Chun W, Kloczkowski A. Hassan M, et al. Genes (Basel). 2024 Jul 31;15(8):1003. doi: 10.3390/genes15081003. Genes (Basel). 2024. PMID: 39202362 Free PMC article. Review. - Comparison of microRNA profiles between benign and malignant salivary gland tumors in tissue, blood and saliva samples: a prospective, case-control study.
Cinpolat O, Unal ZN, Ismi O, Gorur A, Unal M. Cinpolat O, et al. Braz J Otorhinolaryngol. 2017 May-Jun;83(3):276-284. doi: 10.1016/j.bjorl.2016.03.013. Epub 2016 Apr 27. Braz J Otorhinolaryngol. 2017. PMID: 27184509 Free PMC article. - Upregulation of microRNA-23a regulates proliferation and apoptosis by targeting APAF-1 in laryngeal carcinoma.
Zhang XW, Liu N, Chen S, Wang YE, Sun KL, Xu ZM, Fu WN. Zhang XW, et al. Oncol Lett. 2015 Jul;10(1):410-416. doi: 10.3892/ol.2015.3238. Epub 2015 May 20. Oncol Lett. 2015. PMID: 26171041 Free PMC article.
References
- Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4:499–511. - PubMed
- Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–297. - PubMed
- Benoy IH, Salgado R, Van Dam P, Geboers K, Van Marck E, Scharpe S, et al. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res. 2004;10:7157–7162. - PubMed
- Cao Z, Henzel WJ, Gao X. IRAK: a kinase associated with the interleukin-1 receptor. Science. 1996a;271:1128–1131. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P01 AG025901/AG/NIA NIH HHS/United States
- P01 AG025901-02/AG/NIA NIH HHS/United States
- R01 CA036773/CA/NCI NIH HHS/United States
- R37 AG009909/AG/NIA NIH HHS/United States
- P01-AG025901/AG/NIA NIH HHS/United States
- P50 CA058207/CA/NCI NIH HHS/United States
- P50 CA058207-140014/CA/NCI NIH HHS/United States
- R37-AG09909/AG/NIA NIH HHS/United States
- R01-CA36773/CA/NCI NIH HHS/United States
- R37 AG009909-18/AG/NIA NIH HHS/United States
- P50-CA58207/CA/NCI NIH HHS/United States
- R01 CA036773-25/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous